, Joyce Thayane da Conceição dos Santos1
, Márcia Santos Rezende1
, Fernanda Oliveira de Carvalho1
, Érica Santos dos Reis1
, Waneska de Souza Barboza2
, Taise Ferreira Cavalcante1
, Cliomar Alves dos Santos3
, Lucindo José Quintans-Júnior1
, Renata Grespan1
, Cristiane Bani Corrêa1
, Tatiana Rodrigues de Moura1
, Dulce Marta Schimieguel1
, Jullyana de Souza Siqueira Quintans1
, Adriano Antunes de Souza Araújo1
1Federal University of Sergipe, Aracaju, Brazil
2Aracaju City Hall, Municipal Health Department, Aracaju, Brazil
3Government of Sergipe State, Health Foundation Parreiras Horta, Central Laboratory of Public Health (LACEN/SE), Aracaju, Brazil
© 2023, Korean Society of Epidemiology
This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
| Variables | RT-qPCR positive/total, n (%) | Prevalence ratio (95% CI) | p-value | |
|---|---|---|---|---|
| Sex | ||||
| Male | 82/399 (20.6) | 1.00 (reference) | ||
| Female | 29/95 (30.5) | 1.50 (0.94, 2.30) | 0.075 | |
| Age (yr) | ||||
| ≤39 | 68/251 (27.1) | 1.53 (1.03, 2.30) | 0.028 | |
| ≥40 | 43/243 (17.7) | 1.00 (reference) | ||
| Use of public transport | ||||
| No | 16/78 (20.5) | 1.00 (reference) | ||
| Yes | 95/416 (22.8) | 1.11 (0.65, 2.03) | 0.712 | |
| Frequency of use of public transport (times/wk) |
||||
| 1-2 | 15/58 (25.9) | 1.00 (reference) | ||
| 3-4 | 8/35 (22.9) | 0.88 (0.33, 2.22) | 0.795 | |
| ≥5 | 71/310 (22.9) | 0.89 (0.50, 1.67) | 0.653 | |
| COVID-19 vaccine - first dose |
||||
| Oxford-AstraZeneca | 10/56 (17.9) | 1.00 (reference) | ||
| Pfizer-BioNTech | 77/344 (22.4) | 1.25 (0.65, 2.72) | 0.519 | |
| CoronaVac | 12/45 (26.7) | 1.49 (0.59, 3.86) | 0.356 | |
| COVID-19 vaccine - second dose |
||||
| Oxford-AstraZeneca | 2/13 (15.4) | 1.00 (reference) | ||
| Pfizer-BioNTech | 25/115 (21.7) | 1.41 (0.35, 12.31) | 0.699 | |
| CoronaVac | 3/12 (25.0) | 1.63 (0.19, 19.46) | 0.626 | |
| Vaccination schedule | ||||
| Fully vaccinated | 31/145 (21.4) | 1.00 (reference) | ||
| Not vaccinated |
80/349 (22.9) | 1.07 (0.70, 1.68) | 0.753 | |
| Confidence in the protective effect of vaccines | ||||
| Yes | 85/403 (21.2) | 1.00 (reference) | ||
| Preferred not to answer | 5/35 (14.3) | 0.68 (0.21, 1.64) | 0.411 | |
| No | 21/56 (37.5) | 1.78 (1.05, 2.89) | 0.025 | |
SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; RT-qPCR, quantitative reverse-transcriptase polymerase chain reaction; COVID-19, coronavirus disease 2019; CI, confidence interval. Thirteen individuals did not report the frequency of using public transport. Two subjects received the Janssen vaccine, and 42 subjects had no information about the vaccine received as a first dose. Three individuals had no information about the vaccine received. Only 5 individuals were not vaccinated, of whom 1 tested positive for COVID-19.